- Clinical Trials
Major milestones achieved in advancing gene therapies for lung cancer and diabetes
Company to provide update on upcoming clinical trials for the treatment of non-small cell lung cancer and an overview of its diabetes gene therapy
Presentation to Highlight Company’s Recent Advancements on its Upcoming Clinical Trials for the Treatment of Non-Small Cell Lung Cancer
Presentation to Highlight the Company’s Recent Progress on its Upcoming Clinical Trials for the Treatment of Non-Small Cell Lung Cancer
Company passes final release tests of scaled-up clinical grade production to supply drug product for upcoming Acclaim-1 and Acclaim-2 clinical trials in lung cancer
What do small cap and micro cap investors look at? We thought you’d want to know what we discovered when we took a look back at Channelchek’s most popular content of 2020.
And the winners are …
Genprex Inc. (Nasdaq: GNPX), a gene therapy company headquartered in the Texas capital, took the regional title of the year’s largest increase in share value.
Proceeds will add resources for the Company’s Acclaim-1 and Acclaim-2 clinical trials in lung cancer, as well as its pre-clinical programs in cancer and diabetes
Genprex has entered into a securities purchase agreement with a single healthcare-dedicated institutional investor for the purchase and sale of 3,116,884 shares of its common stock at a purchase price of $3.85 per share in a registered direct offering priced at-the-market under Nasdaq rules.
Major Manufacturing Milestone Positions the Company for Success In the Lung Cancer Therapeutics Market, Expected to Grow to $26.3 Billion by 2023